Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 193

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types

Open access
Wagle, Marie-Claire, Kirouac, Daniel, Klijn, Christiaan, Liu, Bonnie, Mahajan, Shilpi, Junttila, Melissa, Moffat, John, Merchant, Mark, Huw, Ling, Wongchenko, Matthew, Okrah, Kwame, Srinivasan, Shrividhya, Mounir, Zineb, Sumiyoshi, Teiko, Haverty, Peter M., Yauch, Robert L., Yan, Yibing, Kabbarah, Omar, Hampton, Garret, Amler, Lukas, Ramanujan, Saroja, Lackner, Mark R., Huang, Shih-Min A. · 2018 · npj Precision Oncology

Abstract

KRAS- and BRAF-mutant tumors are often dependent on MAPK signaling for proliferation and survival and thus sensitive to MAPK pathway inhibitors. However, clinical studies have shown that MEK inhibitors are not uniformly effective in these cancers indicating that mutational status of these oncogenes does not accurately capture MAPK pathway activity. A number of transcripts are regulated by this pathway and are recurrently identified in genome-based MAPK transcriptional signatures. To test whether the transcriptional output of only 10 of these targets could quantify MAPK pathway activity with potential predictive or prognostic clinical utility, we created a MAPK Pathway Activity Score (MPAS) derived from aggregated gene expression. In vitro, MPAS predicted sensitivity to MAPK inhibitors in multiple cell lines, comparable to or better than larger genome-based statistical models. Bridging in vitro studies and clinical samples, median MPAS from a given tumor type correlated with cobimetinib (MEK inhibitor) sensitivity of cancer cell lines originating from the same tissue type. Retrospective analyses of clinical datasets showed that MPAS was associated with the sensitivity of melanomas to vemurafenib (HR: 0.596) and negatively prognostic of overall or progression-free survival in both adjuvant and metastatic CRC (HR: 1.5 and 1.4), adrenal cancer (HR: 1.7), and HER2+ breast cancer (HR: 1.6). MPAS thus demonstrates potential clinical utility that warrants further exploration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41698-018-0051-4

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 193

Metadata

Authors
Wagle, M.-C., Kirouac, D., Klijn, C., Liu, B., Mahajan, S., Junttila, M., Moffat, J., Merchant, M., Huw, L., Wongchenko, M., Okrah, K., Srinivasan, S., Mounir, Z., Sumiyoshi, T., Haverty, P. M., Yauch, R. L., Yan, Y., Kabbarah, O., Hampton, G., Amler, L., Ramanujan, S., Lackner, M. R., & Huang, S.-M. A.
Venue
npj Precision Oncology
Published
2018-03-07
Volume
2
Issue
1
Pages
7-7
ISSN
2397-768X (ISSN-L)
OpenAlex
W2789416018
Cited by
193
References
10
FWCI
4.71
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. https://app.cochat.ai/papers/10.1038/s41698-018-0051-4
The paper
Wagle, M.-C., Kirouac, D., Klijn, C., Liu, B., Mahajan, S., Junttila, M., Moffat, J., Merchant, M., Huw, L., Wongchenko, M., Okrah, K., Srinivasan, S., Mounir, Z., Sumiyoshi, T., Haverty, P. M., Yauch, R. L., Yan, Y., Kabbarah, O., Hampton, G., . . . Huang, S.-M. A. (2018). A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. npj Precision Oncology. https://doi.org/10.1038/s41698-018-0051-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.